Shattuck Labs Inc
$ 4.28
1.18%
24 Feb - close price
- Market Cap 267,674,000 USD
- Current Price $ 4.28
- High / Low $ 4.36 / 4.14
- Stock P/E N/A
- Book Value 1.48
- EPS -0.99
- Next Earning Report 2026-03-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.34 %
- ROE -0.58 %
- 52 Week High 4.89
- 52 Week Low 0.69
About
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapies for the treatment of cancer and autoimmune diseases in the United States. The company is headquartered in Austin, Texas.
Analyst Target Price
$7.25
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-14 | 2025-04-30 | 2025-02-26 | 2024-11-07 | 2024-08-01 | 2024-05-02 | 2024-02-29 | 2023-11-09 | 2023-08-10 | 2023-05-09 | 2023-02-23 |
| Reported EPS | -0.14 | -0.24 | -0.27 | -0.37 | -0.33 | -0.42 | -0.37 | -0.41 | -0.65 | -0.5 | -0.49 | -0.6 |
| Estimated EPS | -0.1432 | -0.245 | -0.2825 | -0.3188 | -0.42 | -0.41 | -0.45 | -0.57 | -0.52 | -0.52 | -0.63 | -0.63 |
| Surprise | 0.0032 | 0.005 | 0.0125 | -0.0512 | 0.09 | -0.01 | 0.08 | 0.16 | -0.13 | 0.02 | 0.14 | 0.03 |
| Surprise Percentage | 2.2346% | 2.0408% | 4.4248% | -16.0602% | 21.4286% | -2.439% | 17.7778% | 28.0702% | -25% | 3.8462% | 22.2222% | 4.7619% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.12 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: STTK
2026-02-16 07:27:10
Shattuck Labs (STTK) is generating significant buzz in biotech and trading circles due to its clinical-stage immuno-oncology therapies. The company is developing fusion protein therapies to fight cancer, representing a high-risk, high-reward investment given it's pre-commercial. The stock is highly volatile and driven by news from clinical trials, making it attractive for speculative investors but risky for casual ones.
2026-02-12 17:27:24
Shattuck Labs, Inc. (NASDAQ:STTK) has received a consensus "Hold" rating from seven brokerages, with an average 12-month price target of $6.20. The stock recently traded down 3.9% at $3.93, with institutional investors holding approximately 58.7% of its shares. The company, a clinical-stage biotechnology firm, focuses on developing immunotherapeutic vaccines for substance use disorders, particularly fentanyl.
2026-02-08 06:57:51
Shattuck Labs has announced that its 2026 Annual Meeting of stockholders will be held on May 28, 2026. The company also set new deadlines for stockholder proposals and nominations, with proposals for proxy materials due by February 15, 2026. All nominations and proposals must adhere to SEC rules and the company's Bylaws.
2026-02-07 06:29:22
Insiders at Shattuck Labs (NASDAQ: STTK) have seen a significant return on their investments despite a recent 12% stock decline. Their original purchases, totaling US$204.4k, are now valued at US$841.2k, representing a net gain of US$637k. The article highlights that insiders have been buying shares over the last year, with Independent Director Clay Siegall making a notable purchase, and currently own 11% of the company.
2026-02-06 18:33:58
Shattuck Labs, Inc. (NASDAQ: STTK) announced its management will participate in a fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium on February 12-13, 2026. The presentation, featuring CEO Taylor Schreiber, CFO Andrew R. Neill, and VP of Clinical Development Michael Choi, will discuss the company's clinical-stage programs, including SL-325, a novel antibody targeting the DR3/TL1A pathway for inflammatory and immune-mediated diseases. A replay will be available on Shattuck Labs' website.
2026-02-06 13:59:32
Shattuck Labs (NASDAQ: STTK) will participate in a prerecorded fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium on February 12, 2026, at 2:00 PM ET. The presentation will feature CEO Taylor Schreiber, CFO Andrew R. Neill, and VP Clinical Development Michael Choi. A replay will be available on the company’s website for 30 days, and the news saw a positive market reaction with STTK gaining 5.60%.
